Long‐Term Efficacy and Immune Responses following Immunization with the RTS,S Malaria Vaccine | Zendy

José A. Stoute | Zendy; Kent E. Kester | Zendy; Urszula Krzych | Zendy; B. T. Wellde | Zendy; T Hall | Zendy; Kate L. White | Zendy; Gregory M. Glenn | Zendy; Chris Ockenhouse | Zendy; Nathalie Garçon | Zendy; R J Schwenk | Zendy; David E. Lanar | Zendy; P. Sun | Zendy; P. Momin | Zendy; Robert A. Wirtz | Zendy; Claudia F. Golenda | Zendy; M. Slaoui | Zendy; Glenn Wortmann | Zendy; Carolyn A. Holland | Zendy; Megan Dowler | Zendy; Joe Cohen | Zendy; W. Ripley Ballou | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Long‐Term Efficacy and Immune Responses following Immunization with the RTS,S Malaria Vaccine

Author(s) -

José A. Stoute,

Kent E. Kester,

Urszula Krzych,

B. T. Wellde,

T Hall,

Kate L. White,

Gregory M. Glenn,

Chris Ockenhouse,

Nathalie Garçon,

R J Schwenk,

David E. Lanar,

P. Sun,

P. Momin,

Robert A. Wirtz,

Claudia F. Golenda,

M. Slaoui,

Glenn Wortmann,

Carolyn A. Holland,

Megan Dowler,

Joe Cohen,

W. Ripley Ballou

Publication year - 1998

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/515657

Subject(s) - malaria vaccine , immunization , vaccination , immune system , immunology , immunity , malaria , medicine , virology , vaccination schedule , antigen , antibody , vaccine efficacy , biology , plasmodium falciparum

The malaria sporozoite vaccine candidate RTS,S, formulated with an oil-in-water emulsion plus the immunostimulants monophosphoryl lipid A and the saponin derivative QS21 (vaccine 3), recently showed superior efficacy over two other experimental formulations. Immunized volunteers were followed to determine the duration of protective immune responses. Antibody levels decreased to between one-third and one-half of peak values 6 months after the last dose of vaccine. T cell proliferation and interferon-gamma production in vitro were observed in response to RTS,S or hepatitis B surface antigen. Seven previously protected volunteers received sporozoite challenge, and 2 remained protected (1/1 for vaccine 1, 0/1 for vaccine 2, and 1/5 for vaccine 3). The prepatent period was 10.8 days for the control group and 13.2 days for the vaccinees (P < .01). Immune responses did not correlate with protection. Further optimization in vaccine composition and/or immunization schedule will be required to induce longer-lasting protective immunity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research